BPC-157 vs LL-37

Name: BPC-157 vs LL-37
Published: 2026-10-24

Updated Oct 24, 20269 sources

Key differences

1LL-37 kills microbes and signals the immune system; BPC-157 is a tissue-repair peptide with no antimicrobial action.
2LL-37 has human topical trials; BPC-157 has almost none. Neither has an injection trial.

Facts from each record, in the same words as their own pages.

BPC-157 and LL-37 side by side
	BPC-157	LL-37
Category	Healing & recovery	Immune, Healing & recovery
Evidence	Limited human data	Limited human data
FDA status	Not FDA approvedRegulatory	Not FDA approvedRegulatory
WADA	Prohibited	Not confirmed
Half-life	Under 30 minutes for the intact peptide in rats and dogs. No human data. The 4-hour figure on many sites has no primary source.Competitor guide	Not measured in humans after injection. One guide cites about 15 to 30 minutes in serum, unsourced.Competitor guide About 30 minutes for the free peptide, cleared by protease breakdown, per one guide; it adds that human data are lacking.Competitor guide About 4 to 6 hours, per one guide, with no source.Competitor guide
Routes	Subcutaneous injection, Oral	Subcutaneous injection, Topical, Other route
Forms	Vial (powder), Capsule, Tablet	Vial (powder), Topical
Reported doses	100 to 750 mcg (subcutaneous injection) 1.6 to 10 mcg/kg (subcutaneous injection) 250 to 1,000 mcg (oral)	25 to 750 mcg (subcutaneous injection) 0.01 to 3.2 mg/mL (topical) 250 mcg (other route)
Most cited frequency	Once daily	Daily
Vial sizes	5 mg, 10 mg, 20 mg, 30 mg, 40 mgCompetitor guide	5 mg, 10 mgVendor guide
Mixed vial keeps	Fridge at 2 to 8 C, dark, never frozen.Competitor guide	Fridge at 2 to 8 C, dark, never frozen.Competitor guide
Protocols on file	23	18

Doses shown are what sources report, labelled by origin. Not medical advice.

9 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.